XERS
Xeris Biopharma Holdings, Inc.
2.03
USD
This page is just a preview of the data found in TrendSpider’s full version
Xeris Biopharma Holdings, Inc. stock is up 20.12% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 December’s closed higher than November. 100% of analysts rate it a buy.
Xeris Biopharma Holdings, Inc. engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis, a therapy for the. treatment of hyperkalemic, hypokalemic. and related variants of primary periodic paralysis.
